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Background: Although the association between inflammation and atherosclerosis is well
established, the biologic events that trigger the local inflammatory response within
plaque are not fully understood. Cytotoxic free radicals and infectious agents, both of
which are associated with an inflammatory response, have previously been implicated in
the initiation and progression of atherosclerosis. In this study, we analyzed carotid
plaque for evidence of oxidative vascular injury by determining the presence and distri-
bution of inducible nitric oxide synthase (iNOS) expression and nitrotyrosine formation
and for evidence of infection with cytomegalovirus.
Methods: Carotid plaque from 51 patients who underwent endarterectomy for either pri-
mary (n = 37) or recurrent (n = 14) stenosis were examined histologically (hematoxylin-
eosin staining and Masson’s trichrome staining) and with immunohistochemistry with
specific antibodies to a –smooth muscle actin, macrophages (CD68), T-lymphocytes
(CD3), and T-cell activation (human leukocyte antigen–DR). Twenty-eight specimens
from patients with primary (n = 15) and recurrent (n = 13) stenosis were examined for
the presence of iNOS and nitrotyrosine with immunohistochemistry and in situ
hybridization (iNOS). Twenty-three additional specimens (22 primary, and 1 recurrent)
were analyzed with antibodies to p53, cytomegalovirus, and the polymerase chain reac-
tion (cytomegalovirus, n = 8).
Results: Primary atherosclerotic lesions were either complex heterogenous cellular
plaques (n = 29) or relatively acellular fibrous plaques (n = 8). Ten of 14 recurrent
plaques were either complex or fibrous lesions, and the remaining four were typical of
myointimal thickening. CD68-positive staining cells were detected in all specimens
regardless of their structural morphology. CD3-positive cells were interspersed between
macrophages in all heterogeneous cellular plaques and only infrequently noted in fibrous
plaques. iNOS and nitrotyrosine immunoreactivity were detected in macrophages and
smooth muscle cells in all complex and fibrous plaques and in two of four myointimal
plaques. The presence of iNOS and nitrotyrosine in plaque correlated with the existence
of symptoms in 80% of primary and 62% of recurrent lesions. Cytomegalovirus was
detected in only two of 23 carotid specimens (9%).
Conclusion: The association between ischemic cerebrovascular symptoms and iNOS and
nitrotyrosine immunoreactivity in complex primary and recurrent carotid plaque and the
infrequent occurrence of cytomegalovirus in primary carotid lesions suggests that ongo-
ing free radical oxidative damage rather than viral infection may contribute to plaque
instability in patients with complex and fibrous carotid plaques. (J Vasc Surg
1999;30:36-50.)
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Although epidemiologic studies have implicated
several risk factors, including hypercholesterolemia,
cigarette smoking, hypertension, and diabetes, in
the cause of atherosclerosis, the influence of these
risk factors on the structure and composition of indi-
vidual plaques is not understood.1,2 In patients with
severe coronary artery disease, sudden death is often
precipitated by coronary thrombosis at the site of
plaque rupture. Burke et al,3 in an autopsy study of
113 cases of sudden cardiac death in male patients,
found evidence of plaque rupture in 69% and plaque
erosion in 31% of the patients with acute coronary
thrombosis. The factors associated with an increase
in the number of vulnerable plaques and the predis-
position to plaque rupture included high total plas-
ma cholesterol concentrations, low levels of high
density lipoprotein, and an elevated total to high
density lipoprotein cholesterol ratio. Cigarette
smoking was an independent risk factor for throm-
bosis irrespective of plaque morphology.3
There is considerable angiographic and morpho-
logic evidence implicating thrombosis at the site of
plaque rupture as the precipitating event in patients
who are symptomatic with coronary artery disease.4-9
Atherosclerotic plaques that are vulnerable to rup-
ture are characterized by a thin fibrous cap and a
dense inflammatory cell infiltrate that consists pre-
dominantly of macrophages and, to a lesser extent, T-
lymphocytes. Although thrombus and an inflamma-
tory response are characteristic features of both coro-
nary and carotid plaque, what initiates this response
is unclear.4-13
Oxidative vascular injury as a result of the ongo-
ing production of oxygen-free radicals and viral infec-
tion are among the etiologic risk factors implicated in
the initiation and progression of atherosclerosis.
There is increasing evidence that nitric oxide (NO)
may play an important role in these events. NO pro-
duced by constitutive nitric oxide synthase is pro-
duced in physiologic concentrations to facilitate
cell–cell communication. In contrast, the expression
of inducible NO synthase leads to the prolonged syn-
thesis of large quantities of NO that in the presence
of superoxide anions released by macrophages,
results in the formation of peroxynitrite, which is
directly toxic to host cells and various pathogens.14,15
Recent reports16-18 implicating viral infestation in
atherosclerosis and restenosis and the known cyto-
toxic effects of NO, led us to test the hypothesis that
cytomegalovirus is present in primary carotid plaque
and that inducible NO synthase (iNOS) is expressed
in carotid plaque of patients with primary and recur-
rent stenosis. Immunohistochemistry was used to
determine the presence and location of iNOS,
nitrotyrosine, and cytomegalovirus. In situ hybridiza-
tion was used to confirm the presence of iNOS mes-
senger RNA and the polymerase chain reaction
(PCR) to detect cytomegalovirus DNA.
MATERIALS AND METHODS
The medical records of 51 patients who under-
went carotid endarterectomy were reviewed to
determine the presenting symptoms and the pres-
ence of risk factors for atherosclerosis. The risk fac-
tors that were recorded included age, gender, hyper-
tension, diabetes, hypercholesterolemia, and smok-
ing habits.
All the patients underwent evaluation initially
with duplex scanning and selective four-vessel
angiography with the Seldinger technique. The indi-
cations for operation included symptomatic (‡ 70%)
or asymptomatic (‡ 80%) diameter reduction.
Endarterectomy was performed with general anes-
thesia with selective use of a shunt. Initially, we used
the standard longitudinal arteriotomy to remove the
plaque. However, it became evident that the use of
this technique often destroyed plaque morphology
and precluded any accurate interpretation of cross-
sectional findings. Subsequently, we have modified
our technique of performing primary endarterectomy
so that the entire plaque is removed en bloc in the dis-
section plane without entering the lumen of the
plaque except proximally in the common carotid
artery and distally beyond the end point. The use of
this technique was not applicable to patients who
underwent redo-endarterectomy. 
Histology. Endarterectomy specimens were
fixed immediately in 10% neutral buffered formalde-
hyde and decalcified in hydrochloric acid. The
plaques were dehydrated in graded alcohol solutions
and embedded in paraffin within 24 hours of
removal. Sections of 5 m m were stained with hema-
toxylin and eosin and Masson’s trichrome stains.
Immunohistochemistry. The cell-type specific
monoclonal antibodies used to identify individual cell
types present and to detect iNOS, nitrotyrosine,
cytomegalovirus, and p53 within the plaque are list-
ed in Table I. Monoclonal antibodies to endothelial
NOS (eNOS) and neuronal NOS (nNOS) were used
to determine whether there was any cross reactivity
between them and iNOS. Paraffin embedded sec-
tions of 5 m m were deparaffinized with xylene and
rehydrated in graded ethanol solutions. The sections
then were microwave-heated in a citrate buffer solu-
tion (pH, 6.6), and endogenous peroxidase activity
was blocked with 3% H2O2. The primary antibody
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was applied for 30 minutes at room temperature.
After being rinsed with phosphate-buffered saline
solution, the biotinylated secondary antibody then
was applied for 30 minutes followed by an avidin-
biotin peroxidase complex. Alkaline phosphatase or
3´3´diaminobenzidine was used as a chromogen, and
the sections were counterstained with hematoxylin.
Both negative and positive controls were used for all
antibody staining. For negative controls, the applica-
tion of the primary antibody was omitted. Lung tis-
sue (CD68), lymph node (CD3), tonsil, and lung
cytomegalovirus pneumonia were used as positive
controls, and brown (diaminobenzidine) or red
(alkaline phosphatase) cytoplasmic or nuclear stain-
ing were considered positive. Multiple consecutive
sections (two to four) from each primary and recur-
rent complex lesion were studied for iNOS and
nitrotyrosine, and the number of positively staining
cells per high power field at a magnification of · 200
were counted. An average of two readings were
recorded in each field examined. Only one to two
specimens were available for analysis from myointi-
mal recurrent lesions. The abundance of each cell
type was estimated with a grading system of 1 to 4+
(minimal to abundant).
In situ hybridization analysis. Antisense and
sense oligonucleotide probes, corresponding to
nucleotides 561 to 600 of the rat vascular smooth
muscle (SMC) iNOS complementary DNA, were 
synthesized on an Applied Biosystems PCR-Mate
oligonucleotide synthesizer (Perkin-Elmer, Applied
Biosystems, Foster City, Calif). We have previously
demonstrated that rat vascular SMC iNOS comple-
mentary DNA shares an 80% homology with human
hepatocyte iNOS.19 The probes were 3´–end labeled
with digoxigenin with an oligonucleotide tailing 
kit (Boehringer Mannheim, Mannheim, Germany).
Labeling was performed according to the manufactur-
er’s instructions, except that the labeling reaction time
was reduced to 15 minutes to minimize probe digestion
and the final ethanol wash was omitted. The hybridiza-
tion buffer contained 5· standard sodium citrate (SSC),
50% formamide, 0.15 mg/mL yeast transfer RNA, and
2· Denhardt’s solution. Prehybridization for 30 min-
utes at room temperature was followed by overnight
hybridization at 42°C with 200 ng of either the anti-
sense or the sense probe. The slides were rinsed briefly
in 1· SSC, then washed in 1· SSC/0.1% sodium dode-
cylsulfate three times for 20 minutes each at 5°C, and
washed once with 1· SSC/0.1% sodium dodecylsulfate
for 20 minutes at a temperature that dropped from
56°C to room temperature. For detection of hybridiza-
tion, sections then were incubated with a monoclonal
antibody to digoxigenin (Boehringer Mannheim), fol-
lowed by horse anti-mouse immunoglobulin and nitro
blue tetrazolium/5-bromo-4-chloro-3-indoxyl phos-
phate substrate solution.
Isolation of cytomegalovirus and detection of
cytomegalovirus DNA. After a portion of each
plaque was obtained for histology and immunohisto-
chemistry, the remainders of the specimens (100 mg)
were homogenized in 1 mL of Eagle’s minimum
essential medium. Centrifuged supernatants of
homogenates were assayed for cytomegalovirus
DNA. Virus isolation also was performed from super-
natant of the homogenates. Human diploid fibrob-
last (MRC-5) cells were used for the isolation of
cytomegalovirus. For this, cells were cultured in a 6
cm–diameter dish with 1 mL of supernatant of the
homogenates. Viral growth was examined micro-
scopically three times per week for 4 weeks, and the
isolates were identified by their types with slow pro-
Table I. Antibodies used for immunohistochemistry
Antibody Antigen Type Source
CD68 Macrophages MAB DAKO
CD3 T-lymphocytes MAB DAKO
HLA-DR Activated cells MAB DAKO
a Actin Smooth muscle MAB DAKO
Factor VIII Endothelial cells MAB DAKO
Cytomegalovirus Inclusion bodies MAB Bio Genex
p53 Nuclear MAB Ventana
iNOS iNOS expressing cells Rb polyclonal Transduction Labs
eNOS Endothelial cells MAB Transduction Labs
nNOS Neuronal tissue MAB Transduction Labs
Nitrotyrosine NO target protein Rb polyclonal Transduction Labs
Digoxygenin Olignucleotide detector Biotinylated polyclonal Boehringer Mannheim
HLA-DR, Human leukocyte antigen–DR; iNOS, inducible nitric oxide synthase; eNOS, endothelial nitric oxide synthase; nNOS neu-
ronal nitric oxide synthase; MAB, monoclonal antibody; Rb, rabbit polyclonal; DAKO, Carpenteria, Calif; Bio Genex, San Ramon, Calif;
Ventana, Tucson, Ariz; Transduction Labs, Lexington, Ky; Boehringer Mannheim, Mannheim, Germany.
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gression of cytomegalovirus. DNA was extracted
from the supernatants of the homogenates by 
the commercial DNA isolators. A part of the
cytomegalovirus immediate early gene was ampli-
fied by nested PCR with primers: 5´CAAGA-
GAAAGATGGACCCTGAT-3´ (sense, 980-1001),
5´-CAGGACATCTTTCTCGGGGTTC-3´ (anti-
sense 1304-1325), and 5´-GACACCCGTGAC-
CAAGGCCACG-3´ (sense, 1157-1178). With a
thermal cycler (GeneAmp PCR System 9600,
Perkin Elmer Cetus, Emeryville, Calif), 35 cycles of
PCR were performed for denaturation at 94°C for
Fig 1. Histologic section of complex plaque showing shoulder region (SR) lipid core with
intraplaque hemorrhage (LC) and relatively acellular fibrous cap (FC). Hematoxylin and eosin
staining, · 64.
Table II. Risk factors for atherosclerosis in
patients with carotid stenosis
Risk factor Primary (n = 37) Recurrent (n = 14)
Age (years) 67 ± 7 68 ± 9
Sex (M:F) 30:7 8:6
Smoking 17 + 8* 5 + 2*
Hypertension 28 4
Diabetes 13 3
Cholesterol (mg/dL) 204 ± 61 265 ± 35
Triglycerides (mg/dL) 279 ± 274 375 ± 123
Data expressed as mean ± SD.
*Number of patients who quit smoking.
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15 seconds, annealing at 60°C for 15 seconds, and
extension at 72°C for 20 seconds. The AD169 strain
of cytomegalovirus was used as a positive control.
RESULTS
Carotid plaques from 39 men and 12 women,
ranging in age from 50 to 81 years (mean, 67 ± 8
years), were evaluated in this study. The risk factors
for atherosclerosis are listed in Table II. All the
patients were undergoing therapy with antiplatelet
agents, and six were undergoing therapy with lipid-
lowering drugs. The presenting symptoms of patients
who underwent primary endarterectomy (n = 37)
were transient ischemic attacks (n = 14), stroke (n =
10), and amaurosis fugax (n = 3). Ten patients were
asymptomatic. Eight of 14 patients with recurrent
stenosis were symptomatic, and the remaining six
had high-grade stenosis (‡ 80%) without symptoms.
The percent stenosis for the patients who underwent
endarterectomy ranged from 70% to 99% diameter
reduction (mean, 85% ± 10%).
Light microscopy showed two distinct types of
primary lesions: complex plaque (n = 29) and rela-
tively acellular fibrous plaque (n = 8). Complex ath-
erosclerotic plaque was characterized by a necrotic
lipid core composed of lipid, cholesterol clefts, cel-
lular debris, calcium deposits, and intraplaque hem-
orrhage (Fig 1). The fibrous plaques were composed
predominantly of collagen, extracellular matrix, and
varying numbers of SMCs surrounding focal aggre-
gations of atheromatous debris. Macrophages and
T-lymphocytes were evident adjacent to the luminal
surface, at the margins of the lipid core and along
fissures within both types of primary plaque. a –SM
actin-positive cells were present in the media and in
varying numbers in the fibrous cap surrounding the
lipid core. An inflammatory cell infiltrate comprised
predominantly of T-lymphocytes in a complex
plaque is shown in Fig 2A. Macrophages and SMCs
in complex and fibrous lesions expressed human
leukocyte antigen–DR (HLA-DR; Fig 2B).
Three distinct types of recurrent plaque were
noted: complex (n = 5) and fibrous (n = 5) plaque
indistinguishable from their primary counterparts,
except for the presence of a suture line, and myoin-
timal thickening (n = 4). The myointimal lesions
were comprised predominantly of SMCs with foci of
macrophages and only occasional T-lymphocytes
(Fig 3). SMCs in these myointimal lesions expressed
HLA-DR.
Twenty-eight (15 primary and 13 recurrent)
plaques were examined with immunohistochemistry
to determine the presence and distribution of iNOS
and nitrotyrosine. Twelve of 15 patients (80%) with
primary lesions (10 of 12 complex, and two of three
fibrous plaque) had ischemic cerebrovascular symp-
toms. Three were asymptomatic. Nine of 13 patients
with recurrent stenosis had complex or fibrous
lesions, and four had myointimal thickening.
Symptoms were present in 62% of patients with
restenosis (six of nine with complex and fibrous
plaque, and two of four with myointimal thicken-
ing). The remaining five were asymptomatic.
Macrophages and SMCs in all complex and fibrous
(primary and recurrent) plaques expressed iNOS
protein and showed evidence of immunoreactivity
with nitrotyrosine (Fig 4A,B). The cells expressing
iNOS and staining positively for nitrotyrosine were
not uniformly distributed throughout the plaque
but were located in areas of plaque adjacent to the
lumen, in the shoulder region of the lipid core, or
along plaque fissures. Nitrotyrosine staining paral-
leled that of iNOS in all the plaques examined. The
percentage of cells expressing iNOS was quite vari-
able, ranging from 20% to 50% in regions adjacent
to the lipid core and from 70% to 100% in cells near
the luminal surface. A representative section of a
complex plaque showing CD68 and iNOS positive
staining of cells adjacent to the lumen is shown in
Fig 5. iNOS and nitrotyrosine immunoreactivity was
detected in SMCs in two of four recurrent myointi-
mal plaques. The SMCs staining positive for iNOS
and nitrotyrosine in fibrous myointimal lesions were
located near the luminal surface with fewer positive
staining cells observed in the deeper layers of the
lesions and media. Between 40% and 70% of the
SMCs showed iNOS and nitrotyrosine staining (Fig
6). A summary of the cell types present in each
plaque and their immunoreactivity is presented in
Table III. In situ hybridization confirmed the pres-
ence of iNOS in macrophages and SMCs (Fig 7). To
determine whether there was any cross reactivity
between iNOS, eNOS, and nNOS expression in
carotid plaque, we stained 10 of the 28 randomly
selected specimens with all three antibodies. eNOS
expression was detected in endothelial cells in
microvessels, and both eNOS and nNOS were
detected in focal aggregates of macrophages (< 5%
of cells) within the plaque areas examined. Only a
few endothelial cells (factor VIII positive) and larg-
er numbers of macrophages and SMCs expressed
iNOS when compared with eNOS or nNOS.
Twenty-three (22 primary, and 1 recurrent) con-
secutive plaques from another cohort of patients who
underwent carotid endarterectomy were examined
with histology and immunohistochemistry for cyto-
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megalovirus. There were 14 complex and eight rela-
tively acellular fibrous primary lesions. The one
patient with restenosis was seen with an asympto-
matic high-grade stenosis and had a complex plaque
at surgery. Symptoms were present in 15 of 23
patients (65%): 12 of 15 (35%) with complex lesions,
and three of eight with fibrous primary plaque. The
remaining eight patients were asymptomatic. We did
not detect the typical cytomegalovirus inclusion bod-
ies in any of the specimens stained with hematoxylin
and eosin. Positive cytomegalovirus staining was
detected in inflammatory cells in one of 23 plaques
Fig 2. A, Brown staining T-lymphocytes in area of inflammation in complex plaque CD3 · 200.
B, Macrophages and smooth muscle cells in complex plaque expressing human leukocyte anti-
gen–DR (arrows, · 200).
A
B
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(4%) examined with immunohistochemistry (Fig
8A,B). This patient was also seropositive for cyto-
megalovirus. Because so few of our specimens con-
tained cytomegalovirus, we performed two addition-
al analyses to verify this observation. We examined
eight of the 23 most recent specimens with both
immunohistochemistry and PCR and detected
cytomegalovirus DNA in only one of the eight spec-
imens (13%) examined (Fig 8C). This specimen
stained negatively with immunohistochemistry. Both
patients were asymptomatic. Because it has been pos-
tulated that impairment of p53 suppressor function
may be one of the potential mechanisms by which
cytomegalovirus may contribute to the progression
of atherosclerosis, immunostaining for p53 was
undertaken and was positive in seven of 23 speci-
Fig 3. Immunostaining section of myointimal plaque showing focus of brown staining
macrophages interspersed between smooth muscle cells (arrows). CD68 · 200.
Table III. Summary of predominant cell types (A) and immunoreactivity (B) in primary and recurrent
carotid plaque
A Cell types
Plaque N MØ SMC TL
Primary Complex 12 ++++ +++ +++
Fibrous 3 ++ +++ +
Recurrent Complex 9 ++++ +++ +++
Intimal 4 + ++++ +
B Immunoreactivity
Plaque N Cell types HLA-DR iNOS NT
Complex and fibrous* 24 MØ +++ ++++ +++
SMC ++ +++ ++
Recurrent intimal 4 (2)† SMC ++ ++++ +++
MØ, Macrophage; SMC, smooth muscle cells; TL, T-lymphocytes; HLA-DR, human leukocyte antigen-DR; iNOS, inducible nitric oxide
synthase; NT, nitrotyrosine; +, minimal; ++, modest; +++, moderate; ++++, abundant.
*Includes both primary and recurrent complex plaques.
†Only two positive specimens.
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mens. Both specimens with cytomegalovirus were
negative for p53.
DISCUSSION
Recent histologic studies of the coronary arteries
of patients with unstable angina or sudden cardiac
death have focused attention on the relationship
between the morphologic characteristics of plaque,
the dynamic role of its structural and cellular ele-
ments, and lesion progression.3-7 An inflammatory
cell infiltrate composed of macrophages and, to a less-
er extent, T-lymphocytes is an integral component of
vulnerable atherosclerotic plaque.8 Several factors
contribute to the instability of atherosclerotic plaque.
Fig 4. Immunostaining of complex plaque stained brown with diaminobenzidine showing
(A) inducible nitric oxide synthase and (B) nitrotyrosine in macrophages and smooth muscle
cells (arrow, · 200).
A
B
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Rupture of a plaque is more likely to occur if the lipid
core exceeds 40% of its overall volume, if the fibrous
cap separating the core from the vessel lumen becomes
attenuated, or if there is an increase in the macrophage
or a decrease in the SMC populations.4-10 Because
ongoing free radical injury and viral infections, both
implicated in the pathogenesis of atherosclerosis,
might be responsible for macrophage recruitment into
plaque, we examined carotid plaque to determine the
presence of iNOS expression and cytomegalovirus
infection.
With immunohistochemistry, we have demon-
Fig 5. A, Immunostaining showing macrophages adjacent to lumen of complex plaque
stained red with alkaline phosphatase CD68 · 200. B, Inducible nitric oxide synthase protein
in macrophages in section from same specimen stained brown with diaminobenzidine · 200. 
A
B
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strated that macrophages, SMCs, and occasionally
endothelial cells in complex primary and recurrent
lesions express iNOS and show evidence of NO
oxidative damage by the presence of its toxic metabo-
lite nitrotyrosine. Wilcox et al20 were unable to detect
iNOS messenger RNA with in situ hybridization in
any of the advanced lesions that they examined. The
reasons for this difference between the observations
of Wilcox et al20 and the present study are not clear
but may be related to the number of specimens exam-
ined, the differences in tissue preservation, or the
probe used. Co-labeling studies confirmed that the
cells expressing iNOS were macrophages and SMCs.
We are unable to explain why occasionally endothelial
cells in complex plaque expressed iNOS. Extensive
immunoreactivity with iNOS and nitrotyrosine was
Fig 6. A, Inducible nitric oxide synthase and B, nitrotyrosine immunostaining showing
brown staining (diaminobenzidine) smooth muscle cells in recurrent myointimal plaque · 400.
A
B
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detected at various locations around atheromatous
lesions: adjacent to the luminal surface, in the shoul-
der region of the lipid core, or along plaque fissures.
Most labeled SMCs were located in the media
beneath the lipid core or in adjacent areas of the
plaque minimally involved with atherosclerosis.
Eighty percent (12 of 15) of patients with primary
stenosis and 62% (eight of 13) of patients with recur-
rent stenosis showing immunoreactivity to iNOS and
nitrotyrosine were symptomatic. The reasons why
eight of 28 patients (40%) with iNOS reactivity in
their plaque did not have symptoms develop are
presently unknown. Whether the absence of symp-
toms in these patients relates to other local, but as yet
undefined, factors within the plaque or to systemic or
hemodynamic factors is presently being evaluated.
The detection of iNOS and nitrotyrosine within the
atheroma suggests ongoing production of NO and its
reaction with superoxide anion to form peroxynitrite.
Usually absent in the intima and media of normal ves-
sels, iNOS expression is increased in areas of inflam-
mation in advanced plaque.20-22
The specific factors that induce iNOS expression
differ somewhat between cell types. In vascular
endothelial cells, as in macrophages, iNOS is
induced by endotoxin from gram-negative bacteria
and by proinflammatory cytokines, such as interfer-
on-g , tumor necrosis factor–a , and interleukin 1.23
Interestingly, SMCs of the arterial intima are more
prone to express iNOS than are their counterparts of
the media because of their enhanced capacity to acti-
vate the iNOS promoter.24 This explains why iNOS
is expressed in the neointima after arterial injury and
in atherosclerotic lesions.25 The presence of HLA-
DR–expressing cells in association with iNOS
expression suggests that interferon-g may contribute
to the induction of iNOS in complex plaque.
How may NO influence plaque stability? First,
unlike NO synthesized by constitutive NO synthase,
which is produced in physiologic concentrations, NO
production resulting from the activity of iNOS is
more substantial and, in the presence of superoxide
anion produced by macrophages, results in the for-
mation of peroxynitrite, which has a direct toxic
effect on proteins, microorganisms, tumor cells, and
vascular SMCs. Depending on the local environment
and the concentration of thiols and tetrahydro-
biopterin, peroxynitrite may either revert to NO or
cause damage by promoting nitration of proteins or
the generation of other toxic radicals including OH–
(Hydroxyl radicals). Free radical–induced cytotoxici-
ty increases cellular debris, enlarging the lipid core
and, as a consequence, the risk of plaque rupture. In
addition to its direct toxic effect on vascular SMCs,
NO has been shown to have an inhibitory effect on
SM proliferation and collagen synthesis. These dele-
Fig 7. In situ hybridization of a complex plaque showing inducible nitric oxide synthase messen-
ger RNA expression in macrophages and smooth muscle cells (arrows, · 200).
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Fig 8. A, Control section (lung) showing immunostaining for cytomegalovirus (arrows, · 400).
B, Cytomegalovirus protein in complex carotid plaque (arrows, · 400). C, Polymerase chain reac-
tion products of cytomegalovirus DNA in complex carotid plaque. Cytomegalovirus DNA was
only detected in sample i as indicated with arrowhead. AD 169 strain of human cytomegalovirus
was used as positive control.
Lanes a-f, i, j, carotid plaque; lanes g, h, aortic and tibial plaque; lane k, negative control.
*Left lane: molecular weight marker, 100 bp ladder. 
A
B
C
terious effects of NO may potentially contribute to
thinning of the fibrous cap and, when combined with
hemodynamic stress, result in plaque rupture.15,26-29
Others have suggested that infectious agents also
may play a role in the initiating events of athero-
sclerotic plaque formation. Herpes simplex virus,
cytomegalovirus, and more recently chlamydia pneu-
moniae have been detected in atherosclerotic
plaques.30-36 Depending on the methodology, cyto-
megalovirus has been detected in 21% to 90% of
advanced atherosclerotic plaques and more recently
in patients with coronary restenosis.16-18,33-36
Cytomegalovirus infection in individuals who are
nonimmunocompromised is usually latent but may
be interrupted by periods of viral reactivation and
recurrent infection. Among the sites for harboring
latent cytomegalovirus are SMCs and leukocytes.
Evidence implicating cytomegalovirus in atheroscle-
rosis is derived from both experimental and clinical
studies. Experimental studies in chickens with
Marek’s lymphomatosis and Japanese quail have
shown an increased susceptibility to dietary-induced
atherosclerosis in susceptible birds infected with
cytomegalovirus.30-37
The strongest evidence implicating cytomeg-
alovirus in the pathogenesis of atherosclerosis is the
correlation between cytomegalovirus antibody titers
and graft atherosclerosis in cardiac transplant recipi-
ents. In a study of 301 cardiac transplant recipients
at Stanford University, cytomegalovirus infection
developed in 91 patients. At 5 years, the incidence
rate of accelerated graft atherosclerosis was nearly
twofold greater (69% vs 37%) in the patients who
were cytomegalovirus infected versus the patients
who were not infected. Furthermore, patients with
cytomegalovirus infection had a 10-fold greater inci-
dence rate of a hemodynamically significant (>50%)
stenosis in their coronary arteries at autopsy.37
Cytomegalovirus might contribute to the initiation
and progression of atherosclerosis by any of several
potential mechanisms. Viral infections may influence
atherogenesis by altering p53 protein levels, either by
enhancing its degradation or by interacting with cellu-
lar p53, increasing its half life. Both processes are
believed to inactivate p53 function and consequently
stimulate SMC proliferation.38-40 We detected p53 in
30% (seven of 23) of the lesions but not in the two
with cytomegalovirus. Viral infections may also
increase the uptake of intracellular lipid and promote
the release of plasminogen activator.17,41,42 Despite
data from several studies suggesting a role for viruses
in the initiation and progression of atherosclerosis, we
detected cytomegalovirus with immunohistochemistry
and PCR in only two of 23 plaques. Because improp-
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er specimen preservation may adversely influence anti-
gen expression, we examined the eight most recent
specimens with both immunohistochemistry and
PCR, yet demonstrated cytomegalovirus DNA in 
only one of eight specimens. Overall, we detected
cytomegalovirus protein and DNA in only 9% of all
plaques examined—half the incidence rate (20%)
reported by Yamashiroya et al43 in the aortas and coro-
nary arteries of young trauma victims.
We are unable to explain the marked discrepan-
cies between the present study and the studies of
Adam et al,16 Hendrix et al,33 and Chiu et al.34
Possibly our patients had low viral concentrations in
their plaque undetectable after preservation by
immunohistochemistry. Furthermore, it is now well
recognized that viral genomes in patients who are
immunosuppressed with latent infection may result
in positive PCR results.44 Whether the same might
apply in non-immunosuppressed hosts is presently
unknown.
Nonetheless, our study suggests that cytomeg-
alovirus is an unlikely cause of plaque instability and,
consequently, symptoms in our patient population.
However, the presence of iNOS and nitrotyrosine in
all complex plaque and in two of four fibrous intimal
lesions and the frequent occurrence of symptoms in
these patients suggest that oxidants derived from
NO, such as peroxynitrite, are being generated in
carotid plaque and may contribute to lesion pro-
gression. Further studies to identify the factors in
plaque responsible for iNOS expression and their
potential role in plaque rupture are currently being
undertaken.
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Dr William C. Krupski (Denver, Colo). Although the
idea was first suggested at the turn of the century, only
recently has evidence accrued that bacterial or viral infec-
tions may play an important role in the initiation and pro-
gression of atherosclerosis. The observation in the late
1970s that a Herpes DNA virus of chickens caused athero-
sclerosis similar to that seen in humans stimulated many
experimental and human studies that now, in aggregate,
support serious consideration of an infectious cause of ath-
erosclerosis. The most commonly identified agents are
Chlamydia pneumoniae, herpes simplex virus, and cytome-
galic virus. The infectious agent that has the strongest asso-
ciation with atherosclerosis is Chlamydia pneumoniae,
found in 50% to 70% of plaques and correlated with disease
severity. Recent trials of the antibiotic azithromycin have
shown a dramatic reduction in cardiovascular complica-
tions in survivors of acute myocardial complications.
The authors are to be commended for their applica-
tion of molecular and immunocytochemical techniques to
determine the presence of cytomegalic virus and iNOS in
carotid endarterectomy specimens. Only 9% of the plaques
had evidence of cytomegalovirus infection, whereas iNOS
expression has apparently been identified in macrophages
and SMC of all complex plaques. The authors conclude
the cytomegalovirus infection affection does not play a
significant role in the initiation or progression of carotid
plaques. Rather, plaque “instability” is caused by iNOS-
induced free radical damage.
I have three questions for the authors:
1. Because the low cytomegalovirus infection rate of
carotid plaques documented in this study is at vari-
ance with all other reports of carotid plaques, how
can they be certain that it is not the result of a false-
negative analysis? Could this result be from inade-
quate specimen preservation and loss of antigenicity?
2. Have the authors attempted to correlate their
findings in carotid plaques by assaying the serum
of those same patients for cytomegalovirus anti-
bodies?
3. iNOS was found consistently in complex plaques and
ascribed by the authors to cause free radical oxidative
damage. Could iNOS expression still be linked to
infection by other agents, such as Chlamydia pneu-
moniae or herpes simplex virus?
Dr Glenn C. Hunter. It is difficult to explain the dis-
crepancy between the results of our study and those of pre-
viously published reports in the literature. We recognized
that specimen preservation and loss of antigenicity may have
significantly influenced our ability to detect cytomegalovirus
protein in plaque. In view of this, we did two things. Initially,
we used p53 immunostaining, which is thought to be the
mechanism by which cytomegalovirus influences cellular
events within plaque. We could only detect p53 staining in
seven of the plaques studied. The second technique that we
used to overcome this difficulty was to do PCR, which
detected a faint signal in one plaque. We therefore conclud-
ed that it is unlikely that cytomegalovirus was present to any
significant extent in the plaques we examined.
We have only assayed the serum of two patients: one
with the positive immunohistochemistry who was also
seropositive, and a cardiac transplant recipient who was
cytomegalovirus seronegative.
It is certainly feasible that chronic microbial infection
may increase iNOS expression in plaque. We have not as
yet completed our studies on Chlamydia pneumoniae, and
therefore I am unable to comment on the presence of
chlamydiae in carotid lesions. We have, however, exten-
sively evaluated the herpes viridae family and have found
virus protein in only a few carotid plaque, although these
viruses are often present in aortic plaque. Therefore, in
conclusion, I would say that, yes, viruses may indeed influ-
ence the expression of iNOS within plaques and that the
inflammatory response to free radicals and infectious caus-
es may in fact be interrelated.
DISCUSSION
